LAUSR

BackgroundThe United States Food and Drug Administration (FDA) recently approved an ultrasound (US) contrast agent for intravenous and intravesical administration in children.ObjectiveSurvey the usage, interest in and barriers for contrast-enhanced US among pediatric radiologists.Materials and methodsThe Contrast-Enhanced Ultrasound Task Force of the Society for Pediatric Radiology (SPR) surveyed the membership of the SPR in January 2017 regarding their current use and opinions about contrast-enhanced US in pediatrics.ResultsThe majority (51.1%, 166) of the 325 respondents (26.7% of 1,218) practice in either a university- or academic affiliated group. The most widely used US contrast agent was Lumason® 52.3% (23/44). While lack of expertise and training were reported barriers, all respondents who are not currently using US contrast agents are considering future use.ConclusionInterest in pediatric contrast US is very high. Education and training are needed to support members who plan to adopt contrast US into practice.